Identification of Significant Prognostic Tissue Markers Associated with Survival in Upper Urinary Tract Urothelial Carcinoma Patients Treated with Radical Nephroureterectomy: A Retrospective Immunohistochemical Analysis Using Tissue Microarray

키워드

참고문헌 (29)

1. Ploeg M, "The present and future burden of urinary bladder cancer in the world", World J Urol, 27, pp.289~293 (2009)
2. Roupret M, "European Association of Urology guidelines on upper urinary tract urothelial cell carcinoma : 2015 update", Eur Urol, 68, pp.868~879 (2015)
3. Raman JD, "Management of patients with upper urinary tract transitional cell carcinoma", Nat Clin Pract Urol, 4, pp.432~443 (2007)
4. Cha EK, "Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinoma", Eur Urol, 61, pp.818~825 (2012)
5. Yates DR, "Cancer-specific survival after radical nephroureterectomy for upper urinary tract urothelial carcinoma : proposal and multi-institutional validation of a post-operative nomogram", Br J Cancer, 106, pp.1083~1088 (2012)
6. Chung PH, "Degree of hydronephrosis predicts adverse pathological features and worse oncologic outcomes in patients with high-grade urothelial carcinoma of the upper urinary tract", Urol Oncol, 32, pp.981~988 (2014)
7. Hwang I, "Preoperative hydronephrosis and diabetes mellitus predict poor prognosis in upper urinary tract urothelial carcinoma", Can Urol Assoc J, 7, pp.E215~20 (2013)
8. Zhang X, "Ureteral tumours showing a worse prognosis than renal pelvis tumours may be attributed to ureteral tumours more likely to have hydronephrosis and less likely to have haematuria", World J Urol, 31, pp.155~160 (2013)
9. Rajcani J, "Immunohistochemical characterization of urothelial carcinoma", Bratisl Lek Listy, 114, pp.431~438 (2013)
10. Mazzucchelli R, "Pathology of upper tract urothelial carcinoma with emphasis on staging", Int J Immunopathol Pharmacol, 27, pp.509~516 (2014)
11. Xu S, "The expression of AEG-1 and cyclin D1 in human bladder urothelial carcinoma and their clinicopathological significance", Int J Clin Exp Med, 8, pp.21222~21228 (2015)
12. Mann SA, "Targeting the programmed cell death-1 path-way in genitourinary tumors : current progress and future perspectives", Curr Drug Metab, 18, pp.700~711 (2017)
13. Bellmunt J, "Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma", Ann Oncol, 26, pp.812~817 (2015)
14. Adachi K, "Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy", Cancer Sci, 106, pp.945~950 (2015)
15. Reis ST, "Immune expression of E-cadherin and alpha, beta and gamma-catenin adhesion molecules and prognosis for upper urinary tract urothelial carcinomas", Int Braz J Urol, 38, pp.466~473 (2012)
16. Cho J, "Prognostic significance of epithelial-mesenchymal transition phenotypes in upper urinary tract urothelial carcinoma", Pathol Res Pract, 214, pp.547~554 (2018)
17. Romkes M, "Association of low CYP3A activity with p53 mutation and CYP2D6 activity with Rb mutation in human bladder cancer", Carcinogenesis, 17, pp.1057~1062 (1996)
18. Lonn U, "Prognostic value of amplification of c-erb-B2 in bladder carcinoma", Clin Cancer Res, 1, pp.1189~1194 (1995)
19. Castillo-Martin M, "Molecular pathways of urothelial development and bladder tumorigenesis", Urol Oncol, 28, pp.401~408 (2010)
20. Cordon-Cardo C, "Molecular alterations associated with bladder cancer initiation and progression", Scand J Urol Nephrol, pp.154~165 (2008)
21. Korkolopoulou P, "The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer", Pathol Res Pract, 193, pp.767~775 (1997)
22. Vollmer RT, "Invasion of the bladder by transitional cell carcinoma : its relation to histologic grade and expression of p53, MIB-1, c-erb B-2, epidermal growth factor receptor, and bcl-2", Cancer, 82, pp.715~723 (1998)
23. Fontana LO, "The expression of p53 and c-erb-2 in transitional cell carcinoma of the kidney pelvis and ureter and its relation to tumor progression and survival", Arch Esp Urol, 55, pp.792~796 (2002)
24. Kunju LP, "Prostate-specific antigen, high-molecular-weight cytokeratin(clone 34betaE12), and", or p63 : an optimal immunohistochemical panel to distinguish poorly differentiated prostate adenocarcinoma from urothelial carcinoma, 2006, pp.125, 675~681
25. Oya M, "Expression of G1-->S transition regulatory molecules in human urothelial cancer", Jpn J Cancer Res, 89, pp.719~726 (1998)
26. El-Gendi S, "Ki-67 and cell cycle regulators p53, p63 and cyclinD1 as prognostic markers for recurrence", progression of bladder urothelial carcinoma, 2018, pp.24, 309~322
27. Amin MB, "Members of the ISUP Immunohistochemistry in Diagnostic Urologic Pathology Group. Best practices recommendations in the application of immunohistochemistry in the bladder lesions:report from the International Society of Urologic Pathology consensus conference", Am J Surg Pathol, 38, pp.e20~34 (2014)
28. Contal C, "An application of checkpoint methods in studying the effect of age on survival in breast cancer", Comput Stat Data Anal, 30, pp.253~270 (1999)
29. Connolly SS, "Nephroureterectomy surgery in the UK in 2012 : British Association of Urological Surgeons(BAUS)Registry data", BJU Int, 116, pp.780~790 (2015)

관련 논문AI추천